Back to top

oncology-screening: Archive

Shaun Pruitt

Top Medical Stocks to Buy for Growth & Performance

The medical sector is crawling with opportunity as indicated in its representation on the Zacks Rank #1 (Strong Buy) list.

HAEPositive Net Change HALONegative Net Change NBIXPositive Net Change

Zacks Equity Research

IDEAYA (IDYA) Up on Upbeat Phase II Bladder & Lung Cancer Data

IDEAYA (IDYA) gains 15% on positive clinical data from its phase II study evaluating the 30 mg monotherapy expansion dose of IDE397 to treat MTAP-deletion urothelial and NSCLC patients.

CGENNegative Net Change IDYANegative Net Change ANVSNegative Net Change ALXONegative Net Change

Zacks Equity Research

Roche's (RHHBY) Combo Therapy Misses Lung Cancer Study Goals

Roche (RHHBY) announces that its mid to late-stage lung cancer study evaluating the tiragolumab combination therapy compared with Keytruda fails to meet primary endpoints.

RHHBYNegative Net Change MRKPositive Net Change CGENNegative Net Change ALXONegative Net Change

Kinjel Shah

Pfizer (PFE) Stock Falls in a Year: Time to Buy, Sell or Hold?

Pfizer (PFE) expects its operational revenues to improve, driven by its in-line products like Vyndaqel, new launches like Abrysvo and newly acquired products, including those acquired from Seagen.

BMYPositive Net Change PFEPositive Net Change BNTXNegative Net Change

Zacks Equity Research

ImmunityBio (IBRX) Gains 17% in the Past Week: Here's Why

ImmunityBio (IBRX) rises 17% in the past week as it announces insurance coverage as well as the treatment of the first patients with its newly approved bladder cancer immunotherapy, Anktiva.

CGENNegative Net Change ANVSNegative Net Change ALXONegative Net Change IBRXNegative Net Change

Zacks Equity Research

AstraZeneca (AZN) Falls on Failure to Meet NSCLC Study OS Goal

AstraZeneca's (AZN) shares decline as it fails to achieve statistically significant overall survival data in a late-stage NSCLC study on Dato-DXd compared with docetaxel.

AZNPositive Net Change ENTXNegative Net Change ANVSNegative Net Change ALXONegative Net Change